Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Keerbergen – page 67

1 980 clinical trials in Keerbergen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Keerbergen at a glance
1 980
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 980 trials in Keerbergen

Open in trial search

Evaluating tirzepatide and letrozole for reducing tumor growth in postmenopausal hormone‑receptor‑positive breast cancer patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:UZ Leuven

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer

Not yet recruiting

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:UZ Leuven

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:ION337
  • Sponsor:Ionis Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Keerbergen

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies in primary care settings. The research examines alternative approaches for patients with chronic PPI use who lack clear long-term usage indications.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Strategies

This innovative study evaluates the effectiveness of on-demand PPI use and alginate formulation therapy compared to traditional gradual dose reduction methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.